Bausch Health Companies Stock News

"Halftime Report" trader Jon Najarian spots unusual activity in the options market.

Shares of Bausch Health Companies Inc. (NYSE:BHC) have been given an average recommendation of Hold by the eleven brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and five have issued a buy recommendation on the company. []

ING Groep NV acquired a new stake in shares of Bausch Health Companies Inc. (NYSE:BHC) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 2,000,000 shares of the companys stock, valued at approximately $55,700,000. Bausch Health Companies accounts for []

CMI Research has released the latest version of its survey report on the Vitreous Tamponades Market, which includes 100+ market data tables, a pie chart, graphs and figures scattered over pages. The market is currently expanding its footprint. The research

The Mad Money host announced a new position in Bausch Health amid the spread of the omicron variant. Here''s what you should know.

The Mad Money host announced a new position in Bausch Health amid the spread of the omicron variant. Here's what you should know.

We believe a sum of the parts is greater than the whole analysis is a good case for buying shares of Bausch Health.

DekaBank Deutsche Girozentrale lowered its stake in shares of Bausch Health Companies Inc. (NYSE:BHC) by 24.1% during the third quarter, Holdings Channel reports. The fund owned 8,129 shares of the companys stock after selling 2,587 shares during the period. DekaBank Deutsche Girozentrales holdings in Bausch Health Companies were worth $228,000 at the end of the []

Following a reduction in the third quarter, Glenview Capital Management's Larry Robbins (Trades, Portfolio) disclosed earlier this week he boosted his stake in Bausch Health Companies Inc. ( BHC , Fin

LOS ANGELES, United States: The report offers an all-inclusive and accurate research study on the global Conjunctivitis Therapeutics market while chiefly focusing on current and historical market scenarios. Stakeholders, market players, investors, and other market participants can significantly benefit from the

Key Players Covered in the Breast Cancer Therapeutics Market Research Report Are Genentech (F. Hoffmann-La Roche Ltd), Eli Lilly and Company, Celgene Corporation, AstraZeneca, Pfizer Inc., Sanofi, Eisai Co. Ltd., Kyowa Kirin, Bristol Myers Squibb, Mayne Pharma Group Limited, Valeant Pharmaceuticals and other key market players. Key Players Covered in the Breast Cancer Therapeutics Market Research Report Are Genentech (F. Hoffmann-La Roche Ltd), Eli Lilly and Company, Celgene Corporation, AstraZeneca, Pfizer Inc., Sanofi, Eisai Co. Ltd., Kyowa Kirin, Bristol Myers Squibb, Mayne Pharma Group Limited, Valeant Pharmaceuticals and other key market players.

Bausch CEO Joseph Papa joined CNBC's Jim Cramer on Tuesday's episode of "Mad Money," discussing the company's plans to separate into three distinct firms.

New Jersey, United States,- Verified Market Research has recently published a research report titled, Diabetic Macular Edema Market Size, and Forecast 2021-2028, Breakdown Data by Manufacturers, Key Regions, Types and Application. Primary and secondary research methodologies have been used to

Complete study of the global Benzodiazepines market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present

Complete study of the global Phenylephrine market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present